[en] Background. Recent studies have shown that many patients treated with growth hormone (GH) during childhood because of idiopathic GH deficiency (GHD) are no longer GH deficient when retested after cessation of GH therapy when final height is achieved. These patients are labelled as transient GHD. We hypothesized that normalization of GH secretion in transient GHD could occur earlier during the course of GH treatment, which could allow earlier cessation of GH treatment. Methods: In a retrospective study, GH secretion was re-evaluated after cessation of GH treatment at final height in 43 patients diagnosed during childhood as idiopathic GHD 10 with multiple pituitary hormonal deficiencies (MPHD) and 33 with isolated GHD ([sGHD]). In a prospective study, GH secretion was re-assessed after interruption of GH treatment given for 1 year in 18 children with idiopathic GHD (2 MPHD, 16 IsGHD). GH secretion was evaluated by glucagon or insulin stimulation tests. Results: In the retrospective study, all the 10 patients with MPHD and 64% of the 33 patients with IsGHD were still deficient at re-evaluation using the paediatric criteria to define GHD (GH peak < 10 ng/ml at provocative test). The proportion of persisting deficiency was greater in patients with complete IsGHD (86%, 12/14 patients) than in patients with partial IsGHD (47%, 9/19 patients). With the criteria proposed in adulthood (GH peak <3 ng/ml), all the 10 patients with MPHD were still considered to be deficient. In contrast, only 15% (5/33 patients) with IsGHD had a maximal GH value < 3 ng/ml (36% of the 14 patients with complete IsGHD and none of the 19 patients with partial IsGHD). In the prospective study, after interruption of GH therapy given for 1 year, the 2 patients with MPHD were still GHD at re-evaluation and they resumed GH treatment. Among the 16 patients with IsGHD, 13 (81%) were still deficient (peak response < 10 ng/ml) after 1 year. Two of the 3 patients in whom GHD was not confirmed at retesting after 1 year GH showed again a deficient response at second retesting. Conclusions: Although many patients diagnosed with IsGHD during childhood have a normalized GH secretory capacity when retested during adulthood, early retesting after interruption of GH treatment given for 1 year during childhood does not enable to determine if GH therapy has to be discontinued before cessation of growth. Copyright (C) 2003 S. Karger AG, Basel.
Research center :
Giga-Neurosciences - ULiège
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Thomas, Muriel
Massa, Guy
Maes, Maes
Beckers, Dominique
Craen, Margarita
Francois, Inge
Heinrichs, Claudine
Bourguignon, Jean-Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Growth hormone (GH) secretion in patients with childhood-onset GH deficiency: Retesting after one year of therapy and at final height
Publication date :
2003
Journal title :
Hormone Research
ISSN :
0301-0163
eISSN :
1423-0046
Publisher :
Karger, Basel, Switzerland
Volume :
59
Issue :
1
Pages :
7-15
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
BSGPE - Belgian Study Group for Pediatric Endocrinology [BE]
Cacciari E, Cicognani A, Pirazzoli P: Final height of patients treated for isolated GH deficiency: Examination of 83 patients. Eur J Endocrinol 1997;137:53-60.
Cutfield W, Lindberg A, Albertson-Wikland K, Chatelain P, Ranke MB, Wilton P: Final height in idiopathic growth hormone deficiency: The KIGS experience. KIGS International Board. Acta Paediatr 1999;suppl 428:72-75.
Thomas M, Massa G, Bourguignon JP, Craen M, De Schepper J, de Zegher F, Dooms L, Du Caju M, François I, Heinrichs C, Malvaux P, Rooman R, Thiry-Counson G, Vandeweghe M, Maes M: Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: The Belgian Experience. Horm Res 2001;55:88-94.
Clayton PE, Price DA, Shalet SM: Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 1987;62:222-226.
Cacciari E, Tassoni P, Parisi G, Pirazzoli P, Zucchini S, Mandini M, Cicognani A, Balsamo A: Pitfalls in diagnosing impaired growth hormone secretion: Retesting after replacement therapy in 63 patients defined as GH deficient. J Clin Endocrinol Metab 1992;74:1284-1289.
Longobardi S, Merola B, Pivonello R, Di Rella F, Di Somma C, Colao A, Ghigo E, Camanni F, Lombardi G: Re-evaluation of growth hormone secretion in 69 adults diagnosed as GH-deficient during childhood. J Clin Endocrinol Metab 1996;81:1244-1247.
Nicolson A, Toogood AA, Rahim A, Shalet SM: The prevalence of severe growth hormone deficiency in adults who received growth hormone therapy replacement in childhood. Clin Endocrinol 1996;44:311-316.
Wacharasindhu S, Cotterill AM, Camacho-Hübner C, Besser GM, Savage MO: Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol 1996;45:553-556.
Juul A, Kastrup KW, Pedersen SA, Skakkebaek NE: Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. J Clin Endocrinol Metab 1997;82:1195-1201.
Tauber M, Moulin P, Pienkowski C, Jouret B, Rochicciolo P: Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997;82:352-356.
Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severi F: Growth hormone (GH) deficiency (GHD) of childhood onset: Reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 1999;84:1324-1328.
Aimaretti G, Baffoni C, Bellone S, Di Vito L, Corneli G, Arvat E, Benso L, Camanni F, Ghigo E: Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. J Clin Endocrinol Metab 2000;85:3693-3699.
Tanner JM, Whitehouse RH, Takaishi M Standards from birth to maturity for height, weight, height velocity and weight velocity: British children 1965. Arch Dis Child 1966;41:454-471,613-635.
Tanner JM: Growth at Adolescence. Oxford, Blackwell Science, 1962.
Tanner JM: Standards for children's height at ages 2-9 years allowing for height of parents. Arch Dis Child 1970;45:755-762.
GH Research Society: Consensus guidelines for the diagnosis and treatment of growth hormone deficiency in childhood and adolescence: Summary statement of the GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3993.
Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency: Consensus guidelines for the diagnosis, treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;93:379-381.
Marin G, Domene HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB Jr: The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994;79:537-541.
Martinez AS, Domene HM, Ropelato MG, Jasper HG, Pennisi PA, Escobar ME, Heinrich JJ: Estrogen priming effect on growth hormone provocative test: A useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab 2000;85:4168-4172.
Andersson AM, Orskov H, Ranke MB, Shalet S, Skakkebaek N: Interpretation of growth hormone provocative tests: Comparison of cut-off values in four European laboratories. Eur J Endocrinol 1995;132:340-343.
Barth JH, Smith JH, Clarkson P: Wide diversity in measurements of growth hormone after stimulation tests in short children are due to assay variability. Ann Clin Biochem 1995;32:369-372.
Celniker AC, Chen AB, Wert RM, Sherman BM: Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469-476.
Chevenne D, Beau N, Léger J, Porquet D: Variability of serum human growth hormone levels in different commercial assays: Specificity of growth hormone-releasing hormone stimulation. Horm Res 1993;40:168-172.
De Boer H, van der Veen EA: Why retest young adults with childhood-onset growth hormone deficiency ? J Clin Endocrinol Metab 1997;82:2032-2036.
Cacciari E, Tassoni P, Cicognani A: Value and limits of pharmacological and physiological tests to diagnose growth hormone deficiency and predict therapy response: First and second retesting during replacement therapy of patients defined as GH deficient. J Clin Endocrinol Metab 1994;79:1663-1669.